ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,141.60
0.69%
Dow Jones
40,287.53
-0.93%
Brent Oil
81.765
-0.63%
Bitcoin
67,433.15
-1.06%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Gilead Sciences Inc (GILD)

  7. Gilead Sciences Inc (GILD) News

GILD

Gilead Sciences (GILD)

Gilead Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GILD
DateTimeSourceHeadlineSymbolCompany
07/22/20244:00AMBusiness WireGilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central AsiaNASDAQ:GILDGilead Sciences Inc
07/17/20249:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GILDGilead Sciences Inc
07/17/20248:50AMBusiness WireChief Medical Officer Merdad Parsey to Leave Gilead Early 2025NASDAQ:GILDGilead Sciences Inc
07/16/20248:30AMBusiness WireGilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024NASDAQ:GILDGilead Sciences Inc
06/26/202410:45AMPR Newswire (Canada)EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA PRÉVENTION DU VIHNASDAQ:GILDGilead Sciences Inc
06/21/20248:00AMIH Market NewsHoneywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues GainsNASDAQ:GILDGilead Sciences Inc
06/20/20248:51AMBusiness WireGilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV PreventionNASDAQ:GILDGilead Sciences Inc
06/17/20246:49AMIH Market NewsGoldman Sachs Raises S&P 500 Forecast for 2024; Disney Secures Deadpool & Wolverine in Chinese Cinemas, and MoreNASDAQ:GILDGilead Sciences Inc
06/14/20243:00AMBusiness WireNew Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of TreatmentNASDAQ:GILDGilead Sciences Inc
06/11/20247:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
06/11/20247:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
06/11/20247:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
06/11/20247:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
06/11/20247:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
06/11/20247:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
06/06/20244:30AMBusiness WireGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNANASDAQ:GILDGilead Sciences Inc
06/05/20242:00AMBusiness WireGilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
06/03/202410:00AMBusiness WireKite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNASDAQ:GILDGilead Sciences Inc
06/03/20249:00AMBusiness WireEncouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System LymphomaNASDAQ:GILDGilead Sciences Inc
06/02/20248:00AMBusiness WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNASDAQ:GILDGilead Sciences Inc
06/02/20248:00AMBusiness WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNASDAQ:GILDGilead Sciences Inc
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
05/31/20248:07AMBusiness WireEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024NASDAQ:GILDGilead Sciences Inc
05/30/20244:45PMBusiness WireGilead Provides Update on Phase 3 TROPiCS-04 StudyNASDAQ:GILDGilead Sciences Inc
05/22/20248:30AMBusiness WireGilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024NASDAQ:GILDGilead Sciences Inc
05/18/20248:30AMBusiness WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
05/14/202410:09AMBusiness WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyNASDAQ:GILDGilead Sciences Inc
05/09/20245:57PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
05/09/20245:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:GILD

Your Recent History

LSE
RTW
Rtw Biotech Opportunities
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved